Welcome to The Ammon-Pinizzotto Center for Women’s Mental Health at MGH. Our Center, established in 1989, has been renamed following the generous gift from Carol Ammon and Dr. Marie Pinizzotto. These resources will be used to realize the overarching mission of the Center.
This website provides a range of current information including discussion of new research findings in women’s mental health and how such investigations inform day-to-day clinical practice. Despite the growing number of studies being conducted in women’s health, the clinical implications of such work are frequently controversial, leaving patients with questions regarding the most appropriate path to follow. Providing these resources to patients and their doctors so that individual clinical decisions can be made in a thoughtful and collaborative fashion dovetails with the mission of our Center.
All pregnant women ages 18-45 are eligible to enroll in the registry. We are currently seeking both controls and those being treated with atypical antipsychotics and/ or antidepressants.
This study will involve 3 brief phone interviews over an 8-month period. The National Pregnancy Registry for Psychiatric Medications is dedicated to evaluating the safety of psychiatric medications that may be taken by women during pregnancy to treat a wide range of mood, anxiety, or psychiatric disorders. The primary goal of this Registry is to determine the frequency of major malformations, such as heart defects, cleft lip, or neural tube defects, in infants exposed to atypical antipsychotics and antidepressants during pregnancy. For more information, please call 1-866-961-2388 or e-mail firstname.lastname@example.org.
Help make the future better for many other women like you.
The MGH Center for Women’s Mental Health
Perinatal and Reproductive Psychiatry Program
Simches Research Building
185 Cambridge St Suite 2200
Boston, MA 02114
To make an appointment:
Massachusetts General Hospital Clinical Program: (617) 724-7792
Location of appointments:
Wang Ambulatory Care Center, Massachusetts General Hospital
15 Parkman St., Floor 8
Boston, MA 02114-3117
October 26, 2016
Phytoestrogens are weak plant-derived estrogens that are structurally similar to estrogen hormones produced by the body. The phytoestrogens contained in soy-based products are called isoflavones. Because they have estrogenic activity, soy isoflavones have long been touted as a treatment for menopausal symptoms, although these clinical studies have yielded mixed results. States of estrogen deficiency and ...Read more
October 25, 2016
Perimenopausal vasomotor symptoms are triggered by a fall in circulating levels of estrogen and other sex steroids. It has been hypothesized that thermoregulatory centres in the hypothalamus play a crucial role in mediating the hot flash response. However, exactly how do hormonal changes bring about these changes in the hypothalamus? If we could understand this ...Read more
Prenatal Antiepileptic Exposure Increases Risk for Malformations: Does High-Dose Folic Acid Reduce Risk?
October 24, 2016
The CDC, the U.S. Public Health Service, and the American College of Obstetricians and Gynecologists (ACOG) all recommend that every woman of reproductive age get 400 micrograms (400 mcg) or 0.4 milligrams of folic acid every day. Most multivitamins contain 400 micrograms or 0.4 milligrams of folic acid. Most prenatal vitamins have approximately 800 micrograms ...Read more
October 22, 2016
There are lots of new articles to review — partly because I haven’t had a chance to pull together the “weekly” roundup for a while, but also because there continues to be a huge number of articles being published in the field of perinatal psychiatry. Some of the most interesting articles on the list are ...Read more
October 21, 2016
Last week, an article looking at the cognitive and motor development of children with prenatal exposure to antidepressants was published in JAMA Psychiatry. Since that time, we have received a lot of questions regarding the article and the clinical implications of its findings. When I did a quick Google search, I found 36 articles reviewing ...Read more
Press Release: Potential Treatment Option for Women Deciding to Discontinue Antidepressants During Pregnancy
October 18, 2016
Massachusetts General Hospital Efficacy Study Centers on EnBrace HR™ SUNSET, LA (PRWEB) OCTOBER 18, 2016: JayMac Pharmaceuticals is sponsoring a study at Massachusetts General Hospital to assess the efficacy of a pre-and post-natal supplement, EnBrace HR™, as a treatment for the prevention of depression in women with a history of Major Depressive Disorder who decide to discontinue ...Read more